Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2025-04-20 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
董事会对独立董事独立性情况评估的专项意见
Board/Management Information Classification · 95% confidence The document is a specialized opinion from the board regarding the independence of the company's independent directors, referencing regulatory guidelines for independent directors and their self-assessment. It does not contain financial statements, earnings data, or other financial report content. It is a governance-related disclosure about board members' independence, which fits best under Board/Management Information (MANG) as it relates to board composition and director status rather than a full governance report or proxy statement. The document length is short and focused on director independence evaluation, not a full governance report or annual report.
2025-04-20 Chinese
关于使用部分闲置募集资金与部分闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Enwei Pharmaceutical Co., Ltd. regarding the use of part of its idle raised funds and part of its idle own funds for cash management. It details the approval by the board and supervisory committee, the investment purpose, types, amounts, risk control measures, and opinions from the board, supervisory committee, and sponsor institution. The document is a formal disclosure about a financing/capital management activity rather than a financial report or earnings release. It does not contain financial statements or detailed financial results but focuses on the company's capital management strategy and regulatory compliance. The document length is 4406 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-04-20 Chinese
2024年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2024 年度董事会工作报告' which translates to '2024 Annual Board of Directors Work Report'. It details the board's activities, meetings, resolutions, committee work, and plans for 2025. It includes financial performance summaries but does not contain full financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). The focus is on the board's work and governance activities over the year, consistent with a Board/Management Information filing. The document length is substantial (9968 characters), indicating it is a full report rather than a brief announcement. Therefore, the most appropriate classification is Board/Management Information (MANG).
2025-04-20 Chinese
2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2024 年年度报告摘要" which translates to "2024 Annual Report Summary". It contains detailed financial data including total assets, net profit, revenue, earnings per share, and shareholder information for the year 2024. It also includes auditor opinions and mentions the audit firm, which is typical for an annual report. The document length is 5716 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement or summary notice. The presence of comprehensive financial metrics and business descriptions confirms this is the actual annual report or a substantial summary thereof, not merely a publication announcement or a regulatory filing. Therefore, the document fits the definition of an Annual Report (10-K).
2025-04-20 Chinese
中信证券股份有限公司关于恩威医药股份有限公司2024年度募集资金存放与使用情况的专项核查意见
Regulatory Filings
2025-04-20 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled "恩威医药股份有限公司 2024 年年度报告全文" which translates to "Enwei Pharmaceutical Co., Ltd. 2024 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, social responsibility, and financial statements. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes signed financial statements, audit reports, and comprehensive financial and operational data for the fiscal year 2024. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K).
2025-04-20 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.